Redeye sees weaker-than-expected US sales, and while this certainly spooked the stock market, we arg...
Huddlestock published on May the 30th, the company’s quarterly report for the first quarter 2024.
On Friday, between 10.00-11.00, CEO Gustav Westman and CFO Gustav Norberg presents the company’s qua...
Redeye returns with an updated view of Saniona following the Q1 report and the recent pipeline updat...
CirChem (”CirChem” eller ”Bolaget”) meddelade den 29 maj 2024 att Bolaget beslutat om en riktad nyem...
Redeye comments on Hoylu’s Q1 2024 report, meeting our ARR forecast, while slightly beating our EBIT...
Japanese sales SEK 29m during first half of 2024, +96% y-o-y Growth driven by largest customer CMP a...
Redeye initiates coverage of Serstech, a rapidly growing player in the niche market for handheld Ram...
Redeye comments on the launch of the new eBarrier score, an AI skin barrier assessment tool for rese...
Redeye updates its estimates on Sleep Cycle following its Q1 2024 report and strategy update.
Redeye updates its estimates of Ependion and discusses both the most recent report and Beijer Electr...
Q1 figures in line – small estimate revisions Awaits closing of merger between 3R and Enauta Reitera...
Cibus acquires six grocery-anchored assets in Sweden for SEK 87.
Beyond Frames currently has six games in production.
The bid is supported by 44.6% of shareholders, representing a bid premium of 74% compared with yeste...
Cantargia levererar ett positivt nyhetsflöde kring bolagets andra kliniska projekt, CAN10.
Redeye comments on the readout from the phase IIa study of naptumomab in combination with docetaxel ...
Fortsatta förhandlingar pågår med obligationsägarna för att nå en långsiktigt finansiell lösning, vi...
Redeye comments on Enviro’s Q1 report, which presented no real surprises.
Redeye provides a research update following the Q1 report published by Lipum earlier today.
